These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 3304966)
1. Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Campoli-Richards DM; Todd PA Drugs; 1987 Aug; 34(2):188-221. PubMed ID: 3304966 [TBL] [Abstract][Full Text] [Related]
2. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Richards DM; Heel RC Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime. Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406 [TBL] [Abstract][Full Text] [Related]
4. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Richards DM; Heel RC; Brogden RN; Speight TM; Avery GS Drugs; 1984 Jun; 27(6):469-527. PubMed ID: 6329638 [TBL] [Abstract][Full Text] [Related]
5. Laboratory evaluation of cefmenoxime: a new cephalosporin. In vitro and in vivo antibacterial activities and pharmacokinetic properties. Matsumoto K; Nagatake T; Uzuka Y; Harada T; Rikitomi N Chemotherapy; 1983; 29(2):80-8. PubMed ID: 6301776 [TBL] [Abstract][Full Text] [Related]
6. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use. Carmine AA; Brogden RN; Heel RC; Speight TM; Avery GS Drugs; 1983 Mar; 25(3):223-89. PubMed ID: 6303743 [TBL] [Abstract][Full Text] [Related]
7. Ceftizoxime: a beta-lactamase-stable, broad-spectrum cephalosporin. Pharmacokinetics, adverse effects and clinical use. Neu HC Pharmacotherapy; 1984; 4(2):47-60. PubMed ID: 6326062 [TBL] [Abstract][Full Text] [Related]
13. [Therapeutic effects of cefmenoxime in the treatment of various infections on infants and children]. Kurashige T; Wakiguchi H; Kitamura I; Ozaki H; Nishibayashi Y; Hamawaki M Jpn J Antibiot; 1982 Nov; 35(11):2579-88. PubMed ID: 6302339 [TBL] [Abstract][Full Text] [Related]
14. Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria. Fuchs PC; Jones RN; Thornsberry C; Barry AL; Gerlach EH; Sommers HM Antimicrob Agents Chemother; 1981 Dec; 20(6):747-59. PubMed ID: 6275784 [TBL] [Abstract][Full Text] [Related]
15. Beta-lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), a novel cephalosporin. Okonogi K; Kuno M; Kida M; Mitsuhashi S Antimicrob Agents Chemother; 1981 Aug; 20(2):171-5. PubMed ID: 6269488 [TBL] [Abstract][Full Text] [Related]
16. [In vitro activity of cefmenoxime (SCE 1365) against 616 hospital strains of gram-negative bacilli chosen for beta-lactam resistance. Comparison with cefotaxime, lamoxactam and ceftazidime]. Le Noc P; Bryskier A; Le Noc D Pathol Biol (Paris); 1983 May; 31(5):351-6. PubMed ID: 6312396 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of cefmenoxime compared with those of other cephalosporins. Schell RF; Smith BR; LeFrock JL; Francisco MA Antimicrob Agents Chemother; 1983 May; 23(5):774-7. PubMed ID: 6307136 [TBL] [Abstract][Full Text] [Related]
18. In-vitro antibacterial activity of L-105, a new cephalosporin. Hikida M; Inoue M; Mitsuhashi S J Antimicrob Chemother; 1986 Nov; 18(5):585-91. PubMed ID: 3492485 [TBL] [Abstract][Full Text] [Related]
19. Cefotaxime. An update of its pharmacology and therapeutic use. Todd PA; Brogden RN Drugs; 1990 Oct; 40(4):608-51. PubMed ID: 2083516 [TBL] [Abstract][Full Text] [Related]
20. Disulfiram-like reactions with newer cephalosporins: cefmenoxime. Kannangara DW; Gallagher K; Lefrock JL Am J Med Sci; 1984; 287(2):45-7. PubMed ID: 6324592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]